Objetivo del estudio: ECD patients with vemurafenib treatment seem to have a stable disease. This study evaluates the possibility of treatment interruption. Other BRAF inhibitors, such as dabrafenib, have recently been proposed for treating BRAF mutated histiocytoses. Other BRAF inhibitor interruption treatment should also be prospectively evaluated.
Investigador principal: Julien Haroche, M.D., Ph.D., HôpitalPitié-Salpêtrière, Paris FRANCE
Datos de contacto: Phone: +33 1 42 17 80 37 e-mail: julien.haroche@psl.aphp.fr
Participación solicitada del paciente: Patients and treating doctors are encouraged to contact Prof. Julien Haroche for more information.
Identificador de ClinicalTrials.gov: NCT02089724